Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 8:17 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 21,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Terminated Phase 2 Interventional Results available

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

NCT03942211
View directory record Official record
Conditions
Sarcoidosis-associated Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1 Interventional

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

NCT02471911
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
KPT-330, Rituximab, Etoposide, Carboplatin, Ifosfamide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 2 Interventional Results available

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

NCT02604511
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Ibrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 3 Interventional Results available

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

NCT02425644
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ponesimod, teriflunomide
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Carlsbad, California • Pomona, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 2, 2026, 8:17 AM EST
Completed Not applicable Interventional

A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women

NCT00000744
View directory record Official record
Conditions
Candidiasis, Candidiasis, Esophageal, HIV Infections
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
16
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 2, 2026, 8:17 AM EST
Terminated Not applicable Interventional Results available

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

NCT00658411
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
deferoxamine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Nov 2, 2026, 8:17 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Wheat Bioactives and Immune Function

NCT02210234
View directory record Official record
Conditions
Endocrine, Nutritional, Metabolic and Immunity Disorders
Interventions
50 grams of whole wheat bran cereal, 100 grams of whole wheat bran cereal
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 2 Interventional Results available

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

NCT00695409
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, carmustine, cytarabine, etoposide, melphalan, ASCT, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1 Interventional

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

NCT00098436
View directory record Official record
Conditions
Leukemia
Interventions
laromustine, temozolomide
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Indianapolis, Indiana • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Nov 2, 2026, 8:17 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Cumulative Irritation Patch Test

NCT01842711
View directory record Official record
Conditions
Allergy, Irritation, Sensitization
Interventions
Not listed
Lead sponsor
Chattem, Inc.
Industry
Eligibility
16 Years to 79 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 2 Interventional

Evaluation of the Bioavailability of Pramlintide

NCT00042471
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
4
States / cities
Orlando, Florida • New Orleans, Louisiana • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Nov 2, 2026, 8:17 AM EST
Recruiting Phase 2 Interventional

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

NCT06905509
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine, Dexamethasone, Epcoritamab, Etoposide Phosphate, Gemcitabine, Ifosfamide, Multigated Acquisition Scan, Oxaliplatin, Rituximab
Procedure · Drug · Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02237209
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Alhambra, California • La Jolla, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Nov 2, 2026, 8:17 AM EST
Completed Not applicable Interventional Results available

Cognitive-behavior Therapy for MS-Related Chronic Pain

NCT00323271
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cognitive-behavior therapy, Interventional
Behavioral · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Nov 2, 2026, 8:17 AM EST
Completed No phase listed Observational

Pneumocystis in Pathogenesis of HIV-associated Emphysema

NCT00869544
View directory record Official record
Conditions
HIV Infections, Pneumocystis Pneumonia, Emphysema, Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 2 Interventional

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

NCT00642499
View directory record Official record
Conditions
Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
36
States / cities
Bakersfield, California • Fresno, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 3 Interventional Results available

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

NCT04268771
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
Biological
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
26
States / cities
Phoenix, Arizona • Palmdale, California • Upland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1 Interventional

A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

NCT01132911
View directory record Official record
Conditions
Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
Interventions
Vorinostat (SAHA), Velcade (PS-341, Bortezomib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 2 Interventional

Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

NCT00038571
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
PS341 (Bortezomib)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
17 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 2 Interventional Results available

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

NCT01215344
View directory record Official record
Conditions
Multiple Myeloma
Interventions
VELCADE, Lenalidomide, Dexamethasone, DVT prophylaxis, Bisphosphonates, Liposomal doxorubicin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Memphis, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1Phase 2 Interventional Results available

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

NCT02133664
View directory record Official record
Conditions
Multiple Sclerosis, Cognition
Interventions
lipoic acid and omega-3 fatty acids, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Nov 2, 2026, 8:17 AM EST
Completed Phase 1 Interventional

A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

NCT00001444
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Neoplasm, Prostatic Neoplasm
Interventions
7-hydroxystaurosporine (UCN-01)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 2, 2026, 8:17 AM EST